Periodic Safety Update Reports Flashcards
7 cards from real PVC practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Periodic Safety Update Reports flashcards as text
Under ICH E2C(R2), which of the following is NOT a required section of the PSUR?
Answer: Post-market clinical trial protocols
The PSUR does not require inclusion of post-market clinical trial protocols; it focuses on safety data summaries, signal evaluations, and benefit-risk analysis.
How is cumulative patient exposure typically expressed in a PSUR?
Answer: As patient-years, units sold, or prescriptions dispensed with appropriate caveats
Cumulative exposure is commonly expressed as patient-years, units sold, or prescriptions dispensed, with acknowledged limitations of each method.
What is the purpose of the 'Summary Tabulations' section in a PSUR?
Answer: To present cumulative and interval counts of adverse events by system organ class
Summary tabulations aggregate adverse event counts by system organ class for both the reporting interval and cumulatively, enabling trend analysis.
In the PSUR, the 'Interval' data refers to which time period?
Answer: The data collected only within the current reporting period
Interval data covers only the safety information collected during the specific reporting period covered by the current PSUR.
Which regulatory agency uses the term 'Periodic Benefit-Risk Evaluation Report' (PBRER) interchangeably with PSUR?
Answer: EMA (European Medicines Agency)
The EU/EMA adopted the ICH E2C(R2) format calling it the PBRER, emphasizing the integrated benefit-risk evaluation component.
When a product has multiple strengths and formulations, how are PSURs typically structured?
Answer: A single PSUR covering all strengths and formulations under one active substance
ICH E2C(R2) recommends a single PSUR for all formulations, strengths, and indications of a product containing the same active substance.
What is the significance of a 'lack of efficacy' report in the context of PSURs for certain product types?
Answer: It is particularly important for vaccines and anti-infectives where treatment failure may indicate a safety concern
For vaccines and anti-infectives, lack of efficacy can be a critical safety signal (e.g., failure to protect against infection), and must be reported and analyzed in PSURs.